MCID: SVR005
MIFTS: 50

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 54 15 71 32
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 71
Severe Pre-Eclampsia, Postpartum Condition or Complication 71
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 34 642.50
ICD10 32 O14.1
UMLS 71 C0156669 C0156672 C0156673 more

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to acute kidney failure and thrombotic microangiopathy, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Azithromycin and Tinzaparin have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 367, show less)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.2 GPT CFH ALB
2 thrombotic microangiopathy 31.0 VEGFA CFH
3 hellp syndrome 30.9 VEGFA SERPINC1 PGF LGALS13 LEP GPT
4 eclampsia 30.9 VEGFA SERPINC1 PGF PAPPA LGALS13 HLA-G
5 antiphospholipid syndrome 30.7 VCAM1 SERPINC1 PGF F5 CFH C3
6 mild pre-eclampsia 30.7 VEGFA VCAM1 PGF PAPPA LGALS13 LEP
7 oligohydramnios 30.6 PGF PAPPA FGR
8 membranoproliferative glomerulonephritis 30.5 CFH C3 ALB
9 pericardial effusion 30.5 VEGFA HIF1A GPT ALB
10 end stage renal disease 30.5 VEGFA CFH C3 ALB
11 hyperuricemia 30.5 LEP GPT ALB
12 brain edema 30.3 VEGFA MMP9 ALB
13 kidney disease 30.3 VCAM1 LEP FN1 CFH C3 ALB
14 cholelithiasis 30.3 LEP GPT ALB
15 hyperglycemia 30.3 VCAM1 LEP HIF1A ALB
16 gestational diabetes 30.2 PGF PAPPA LEP ALB
17 glomerulonephritis 30.2 VCAM1 FN1 CFH C3 ALB
18 purpura 30.2 SERPINC1 C3 APOH
19 ovarian hyperstimulation syndrome 30.2 VEGFA F5 ALB
20 disseminated intravascular coagulation 30.1 SERPINC1 GPT FN1 F5
21 hemolytic-uremic syndrome 30.1 SERPINC1 CFH C3
22 polyarteritis nodosa 30.0 VCAM1 GPT APOH
23 thrombotic thrombocytopenic purpura 30.0 SERPINC1 CFH C3 APOH
24 autoimmune disease 29.9 VCAM1 MMP9 HLA-G C3 APOH
25 amaurosis fugax 29.9 MMP9 F5
26 liver cirrhosis 29.9 SERPINC1 LEP GPT ALB
27 migraine with or without aura 1 29.8 MMP9 LEP APOH ALB
28 thrombophilia due to thrombin defect 29.8 SERPINC1 F5 APOH
29 placenta praevia 29.7 PGF PAPPA
30 papilledema 29.7 VEGFA SERPINC1 APOH
31 cardiovascular system disease 29.6 VCAM1 SERPINC1 LEP APLN ALB
32 chronic kidney disease 29.6 VEGFA VCAM1 MMP9 LEP FN1 CFH
33 placental abruption 29.6 SERPINC1 PGF PAPPA HLA-G F5 APOH
34 placental insufficiency 29.5 VEGFA SERPINC1 PGF PAPPA LEP HIF1A
35 hepatic infarction 29.5 SERPINC1 GPT APOH ALB
36 endocarditis 29.5 VCAM1 SERPINC1 APOH ALB
37 cerebrovascular disease 29.5 VCAM1 MMP9 LEP F5 APOH
38 pulmonary embolism 29.4 SERPINC1 F5 APOH ALB
39 thrombophilia due to activated protein c resistance 29.3 SERPINC1 F5 APOH
40 antithrombin iii deficiency 29.3 SERPINC1 F5 APOH
41 intracranial hypertension 29.2 SERPINC1 F5 APOH ALB
42 thrombosis 29.2 VCAM1 SERPINC1 F5 APOH
43 homocysteinemia 29.2 VCAM1 SERPINC1 F5 APOH ALB
44 pre-eclampsia 29.1 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
45 protein s deficiency 29.1 SERPINC1 F5 APOH
46 budd-chiari syndrome 29.0 SERPINC1 F5 APOH
47 blood coagulation disease 29.0 VEGFA SERPINC1 GPT F5 APOH ALB
48 thrombocytopenia 28.8 SERPINC1 MMP9 HIF1A GPT F5 CFH
49 hypertension, essential 28.6 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
50 placenta disease 28.6 VEGFA SERPINC1 PGF PAPPA HLA-G F5
51 stroke, ischemic 28.6 VEGFA SERPINC1 MMP9 F5 APOH ALB
52 vascular disease 28.3 VEGFA VCAM1 SERPINC1 MMP9 LEP FN1
53 dipetalonemiasis 10.6 GPT ALB
54 intravascular papillary endothelial hyperplasia 10.6 VEGFA HIF1A
55 heterophyiasis 10.6 GPT ALB
56 pyridoxine deficiency anemia 10.6 VCAM1 GPT
57 atypical hemolytic uremic syndrome with complement gene abnormality 10.5 CFH C3
58 intestinal perforation 10.5 VEGFA GPT ALB
59 hepatic tuberculosis 10.5 GPT ALB
60 ascending cholangitis 10.5 GPT ALB
61 ankylosing spondylitis 1 10.5 GPT ALB
62 dense deposit disease 10.5 CFH C3
63 sick building syndrome 10.5 VEGFA MMP9 LEP
64 pneumococcal meningitis 10.5 MMP9 C3
65 acroosteolysis 10.5 VEGFA ALB
66 genetic atypical hemolytic-uremic syndrome 10.5 CFH C3
67 splenic abscess 10.5 GPT ALB
68 critical illness polyneuropathy 10.5 GPT ALB
69 exanthem 10.5 VEGFA GPT ALB
70 protein-energy malnutrition 10.5 LEP GPT ALB
71 lateral ventricle meningioma 10.5 MMP9 HIF1A
72 c3 glomerulopathy 10.5 CFH C3
73 epidermolysis bullosa dystrophica, autosomal dominant 10.5 C3 ALB
74 prediabetes syndrome 10.5 LEP GPT ALB
75 pyuria 10.5 GPT C3 ALB
76 chronic venous insufficiency 10.5 VEGFA VCAM1 MMP9
77 henoch-schoenlein purpura 10.5 VCAM1 C3 ALB
78 intestinal obstruction 10.5 VEGFA GPT ALB
79 macular degeneration, age-related, 9 10.5 VCAM1 C3
80 dengue hemorrhagic fever 10.5 VEGFA GPT ALB
81 heart aneurysm 10.5 MMP9 GPT ALB
82 coronary aneurysm 10.5 MMP9 GPT ALB
83 klatskin's tumor 10.5 MMP9 GPT ALB
84 carotid stenosis 10.5 VEGFA VCAM1 MMP9
85 louse-borne relapsing fever 10.4 CFH C3
86 hair disease 10.4 VEGFA GPT ALB
87 peripheral artery disease 10.4 VEGFA VCAM1 HIF1A
88 iga glomerulonephritis 10.4 CFH C3 ALB
89 pulmonary emphysema 10.4 VEGFA MMP9 ALB
90 varicocele 10.4 LEP HIF1A ALB
91 thyroid gland disease 10.4 LEP GPT ALB
92 arteries, anomalies of 10.4 VEGFA VCAM1 LEP ALB
93 glucose metabolism disease 10.4 VEGFA LEP GPT ALB
94 alport syndrome 10.4 VEGFA CFH ALB
95 secondary progressive multiple sclerosis 10.4 VEGFA MMP9 LEP ALB
96 acquired metabolic disease 10.4 VEGFA LEP GPT ALB
97 acalculous cholecystitis 10.4 GPT ALB
98 hepatic encephalopathy 10.4 MMP9 GPT ALB
99 pulmonary edema 10.4
100 severe nonproliferative diabetic retinopathy 10.4 VEGFA PGF ALB
101 portal hypertension 10.4 VEGFA GPT ALB
102 autoimmune atherosclerosis 10.4 VCAM1 APOH
103 background diabetic retinopathy 10.4 VEGFA PGF ALB
104 eye degenerative disease 10.4 VEGFA CFH C3 ALB
105 bacterial meningitis 10.4 MMP9 C3 ALB
106 decubitus ulcer 10.4 VEGFA MMP9 FN1 ALB
107 chronic ulcer of skin 10.4 VEGFA MMP9 FN1 ALB
108 microvascular complications of diabetes 1 10.4 VEGFA VCAM1 MMP9 HIF1A
109 blood group, globoside system 10.4 VEGFA PGF ALB
110 macular retinal edema 10.3 VEGFA PGF ALB
111 intussusception 10.3 VEGFA PGF ALB
112 respiratory distress syndrome in premature infants 10.3
113 newborn respiratory distress syndrome 10.3
114 intracranial berry aneurysm 10.3 VCAM1 MMP9 ALB
115 endophthalmitis 10.3 VEGFA PGF ALB
116 kuhnt-junius degeneration 10.3 VEGFA PGF CFH
117 schistosomiasis 10.3 VEGFA GPT ALB
118 corneal disease 10.3 VEGFA MMP9 FN1 ALB
119 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.3 VEGFA FN1 CFH ALB
120 lyme disease 10.3 MMP9 CFH C3
121 retinal perforation 10.3 VEGFA PGF FN1
122 intrahepatic cholestasis of pregnancy 10.3 MMP9 HLA-G HIF1A GPT
123 hydronephrosis 10.3 VEGFA MMP9 HIF1A ALB
124 autosomal genetic disease 10.3 VEGFA FN1 CFH ALB
125 meningitis 10.3 VEGFA MMP9 C3 ALB
126 fournier gangrene 10.3 SERPINC1 ALB
127 acute pyelonephritis 10.3 PGF GPT ALB
128 pyelonephritis 10.3 PGF GPT ALB
129 odontogenic myxoma 10.3 VEGFA MMP9
130 diabetic macular edema 10.3 VEGFA PGF HIF1A
131 trypanosomiasis 10.3 VCAM1 HLA-G GPT C3 ALB
132 apnea, obstructive sleep 10.3 VEGFA LEP HIF1A GPT ALB
133 ectopic pregnancy 10.3 VEGFA PGF PAPPA
134 tongue disease 10.3 VEGFA MMP9 HIF1A
135 atherosclerosis susceptibility 10.3 VEGFA VCAM1 MMP9 LEP ALB
136 peripheral nervous system disease 10.3 VEGFA LEP GPT FN1 ALB
137 kawasaki disease 10.3 MMP9 GPT ALB
138 renal fibrosis 10.3 MMP9 HIF1A FN1 ALB
139 retinal detachment 10.3
140 hydatidiform mole, recurrent, 1 10.3
141 yemenite deaf-blind hypopigmentation syndrome 10.3
142 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.3
143 gestational trophoblastic neoplasm 10.3
144 protein-losing enteropathy 10.3 VEGFA SERPINC1 ALB
145 diabetes mellitus, type i 10.3 VEGFA VCAM1 LEP C3 ALB
146 hepatic coma 10.2 SERPINC1 GPT ALB
147 esophageal varix 10.2 SERPINC1 GPT ALB
148 blood protein disease 10.2 VEGFA SERPINC1 ALB
149 compartment syndrome 10.2 SERPINC1 GPT ALB
150 hypersplenism 10.2 SERPINC1 GPT ALB
151 acquired angioedema 10.2 F5 C3
152 retinal hemangioblastoma 10.2 VEGFA HIF1A
153 diarrhea 10.2 LEP GPT CFH C3 ALB
154 degeneration of macula and posterior pole 10.2 VEGFA PGF CFH C3
155 bullous retinoschisis 10.2 VEGFA F5 CFH
156 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
157 deficiency anemia 10.2
158 asphyxia neonatorum 10.2
159 hemolytic anemia 10.2
160 chromosomal triplication 10.2
161 partial hydatidiform mole 10.2
162 gliosarcoma 10.2 VEGFA MMP9 HIF1A FN1 ALB
163 endocardium disease 10.2 SERPINC1 FN1 ALB
164 cancer-associated retinopathy 10.2 VEGFA PGF
165 sleep apnea 10.2 VEGFA VCAM1 LEP HIF1A GPT ALB
166 suppression of tumorigenicity 12 10.2 VEGFA MMP9 HIF1A FN1 ALB
167 moyamoya disease 1 10.2 VEGFA SERPINC1 MMP9
168 ductal carcinoma in situ 10.2 VEGFA MMP9 HIF1A
169 persistent fetal circulation syndrome 10.2 VEGFA PGF LEP HLA-G ALB
170 prothrombin deficiency 10.2 SERPINC1 APOH
171 hepatic vascular disease 10.2 VEGFA SERPINC1 GPT ALB
172 osteonecrosis 10.2 VEGFA SERPINC1 HIF1A
173 limb ischemia 10.2 VEGFA PGF MMP9 HIF1A
174 alpha-1-antitrypsin deficiency 10.2 SERPINC1 GPT ALB
175 syphilis 10.1 GPT FN1 APOH ALB
176 granulomatous hepatitis 10.1 GPT ALB
177 pain agnosia 10.1
178 rickets 10.1
179 lipoprotein quantitative trait locus 10.1 VEGFA VCAM1 MMP9 HIF1A GPT ALB
180 respiratory failure 10.1
181 patau syndrome 10.1
182 cortical blindness 10.1
183 thrombophilia 10.1
184 triploidy 10.1
185 headache 10.1
186 microvascular complications of diabetes 5 10.1 VEGFA VCAM1 PGF HIF1A ALB
187 autoimmune disease of musculoskeletal system 10.1 C3 APOH ALB
188 may-thurner syndrome 10.1 F5 APOH
189 pulmonary fibrosis, idiopathic 10.1 VEGFA VCAM1 MMP9 HIF1A FN1 ALB
190 cataract 10.1 VEGFA LEP HIF1A GPT FN1 ALB
191 venous insufficiency 10.1 VEGFA VCAM1 MMP9 F5
192 myeloma, multiple 10.1 VEGFA VCAM1 MMP9 HIF1A FN1 ALB
193 acanthamoeba keratitis 10.1 F5 APOH
194 marantic endocarditis 10.0 SERPINC1 APOH
195 livedoid vasculitis 10.0 SERPINC1 APOH
196 pneumonia 10.0 MMP9 GPT FN1 ALB
197 pregnancy loss, recurrent 1 10.0 HLA-G F5 APOH
198 autoimmune disease of cardiovascular system 10.0 SERPINC1 C3 APOH
199 sticky platelet syndrome 10.0 SERPINC1 F5
200 creatinine clearance quantitative trait locus 10.0
201 amnestic disorder 10.0
202 acute myocardial infarction 10.0 SERPINC1 PAPPA MMP9 FN1
203 atrial standstill 1 10.0
204 coarctation of aorta 10.0
205 renal cell carcinoma, nonpapillary 10.0
206 pheochromocytoma 10.0
207 neural tube defects 10.0
208 preeclampsia/eclampsia 1 10.0
209 enterocolitis 10.0
210 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
211 thrombocytopenia-absent radius syndrome 10.0
212 helicobacter pylori infection 10.0
213 patent ductus arteriosus 1 10.0
214 preeclampsia/eclampsia 4 10.0
215 preeclampsia/eclampsia 5 10.0
216 peripartum cardiomyopathy 10.0
217 adrenal gland pheochromocytoma 10.0
218 cardiac arrest 10.0
219 hemiplegia 10.0
220 adult respiratory distress syndrome 10.0
221 hemopericardium 10.0
222 cardiac tamponade 10.0
223 nephrotic syndrome 10.0
224 acute kidney tubular necrosis 10.0
225 hypothyroidism 10.0
226 cranial nerve palsy 10.0
227 congestive heart failure 10.0
228 scotoma 10.0
229 hypertensive encephalopathy 10.0
230 fatty liver disease 10.0
231 prothrombin-related thrombophilia 10.0
232 sickle cell disease 10.0
233 48,xyyy 10.0
234 bronchopulmonary dysplasia 10.0
235 cytokine deficiency 10.0
236 diploid-triploid mosaicism 10.0
237 encephalopathy 10.0
238 hypoxia 10.0
239 aplastic anemia 10.0 VEGFA VCAM1 SERPINC1 FN1 ALB
240 catastrophic antiphospholipid syndrome 9.9 F5 CFH APOH
241 retinal vascular disease 9.9 VEGFA VCAM1 PGF HIF1A FN1 ALB
242 polycythemia 9.9 VEGFA HIF1A F5
243 arteriosclerosis 9.9 VCAM1 SERPINC1 MMP9 HIF1A GPT
244 splenic infarction 9.9 SERPINC1 GPT APOH ALB
245 pulmonary hypertension 9.9 VEGFA SERPINC1 HIF1A FN1 ALB
246 post-thrombotic syndrome 9.9 VCAM1 SERPINC1 F5
247 pancreatic adenocarcinoma 9.9 VEGFA PGF MMP9 HIF1A ALB
248 hydrops fetalis, nonimmune 9.9
249 myasthenia gravis 9.9
250 ocular motor apraxia 9.9
251 body mass index quantitative trait locus 1 9.9
252 aspiration pneumonia 9.9
253 chorioamnionitis 9.9
254 endometritis 9.9
255 pancytopenia 9.9
256 von willebrand's disease 9.9
257 amenorrhea 9.9
258 acute pancreatitis 9.9
259 anuria 9.9
260 liver disease 9.9
261 systemic scleroderma 9.9
262 pancreatitis 9.9
263 postpartum depression 9.9
264 inflammatory myopathy with abundant macrophages 9.9
265 inherited blood coagulation disease 9.9 SERPINC1 F5 ALB
266 takayasu arteritis 9.9 VCAM1 SERPINC1 MMP9 APOH
267 puerperal pulmonary embolism 9.9 SERPINC1 PGF APOH
268 cerebral sinovenous thrombosis 9.8 F5 APOH
269 blood platelet disease 9.8 VEGFA SERPINC1 GPT APOH ALB
270 afibrinogenemia, congenital 9.8 SERPINC1 F5 C3
271 homocystinuria 9.8 SERPINC1 LEP F5 ALB
272 body mass index quantitative trait locus 11 9.8 VEGFA VCAM1 LEP HIF1A GPT CFH
273 alzheimer disease 9.7
274 total anomalous pulmonary venous return 1 9.7
275 colorectal cancer 9.7
276 fibromuscular dysplasia 9.7
277 hypercholesterolemia, familial, 1 9.7
278 hypertriglyceridemia, familial 9.7
279 chromosome 2q35 duplication syndrome 9.7
280 down syndrome 9.7
281 anemia, autoimmune hemolytic 9.7
282 proteasome-associated autoinflammatory syndrome 1 9.7
283 insulin-like growth factor i 9.7
284 anxiety 9.7
285 graft-versus-host disease 9.7
286 leptin deficiency or dysfunction 9.7
287 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
288 adrenal cortical carcinoma 9.7
289 restless legs syndrome 9.7
290 metabolic acidosis 9.7
291 paraganglioma 9.7
292 paroxysmal nocturnal hemoglobinuria 9.7
293 dextro-looped transposition of the great arteries 9.7
294 polycystic kidney disease 9.7
295 aortic dissection 9.7
296 glucose intolerance 9.7
297 renal hypertension 9.7
298 gastric ulcer 9.7
299 malignant hypertension 9.7
300 choledocholithiasis 9.7
301 multicentric reticulohistiocytosis 9.7
302 allergic hypersensitivity disease 9.7
303 acute cystitis 9.7
304 cholestasis 9.7
305 mitral valve stenosis 9.7
306 optic nerve disease 9.7
307 myeloproliferative neoplasm 9.7
308 thrombocytosis 9.7
309 iron metabolism disease 9.7
310 lipid metabolism disorder 9.7
311 neurilemmoma 9.7
312 neurilemmoma of the fifth cranial nerve 9.7
313 aspiration pneumonitis 9.7
314 ischemia 9.7
315 cellulitis 9.7
316 placenta accreta 9.7
317 hemoglobinuria 9.7
318 paraplegia 9.7
319 hyperthyroidism 9.7
320 periodontitis 9.7
321 appendicitis 9.7
322 polyhydramnios 9.7
323 lung disease 9.7
324 neuropathy 9.7
325 autosomal dominant polycystic kidney disease 9.7
326 krukenberg carcinoma 9.7
327 hypoglycemia 9.7
328 pulmonary venous return anomaly 9.7
329 depression 9.7
330 nonsyndromic paraganglioma 9.7
331 dysphagia 9.7
332 bicornuate uterus 9.7
333 pik3ca-related overgrowth syndrome 9.7
334 peripheral vascular disease 9.7 VEGFA VCAM1 SERPINC1 F5 ALB
335 spinal cord infarction 9.7 SERPINC1 F5 APOH
336 sudden sensorineural hearing loss 9.7 SERPINC1 F5 APOH
337 prothrombin deficiency, congenital 9.7 SERPINC1 F5 APOH
338 sneddon syndrome 9.7 SERPINC1 F5 APOH
339 intracranial thrombosis 9.7 SERPINC1 F5 APOH
340 factor xii deficiency 9.7 SERPINC1 F5 APOH
341 peripheral vertigo 9.7 SERPINC1 F5 APOH
342 purpura fulminans 9.7 SERPINC1 F5 APOH
343 legg-calve-perthes disease 9.7 SERPINC1 F5 APOH
344 meningococcemia 9.7 SERPINC1 F5
345 protein c deficiency 9.7 SERPINC1 F5 APOH
346 portal vein thrombosis 9.7 SERPINC1 F5 APOH
347 intermittent claudication 9.6 VEGFA SERPINC1 PGF APOH ALB
348 retinal vein occlusion 9.6 VEGFA SERPINC1 F5 APOH
349 nonarteritic anterior ischemic optic neuropathy 9.6 VEGFA SERPINC1 F5 APOH
350 macular degeneration, age-related, 1 9.6 VEGFA PGF MMP9 HIF1A FN1 CFH
351 thrombophlebitis 9.6 SERPINC1 F5 APOH ALB
352 patent foramen ovale 9.5 SERPINC1 F5 APOH ALB
353 eye disease 9.5 VEGFA VCAM1 PGF MMP9 HIF1A FN1
354 varicose veins 9.5 VEGFA SERPINC1 MMP9 HIF1A FN1 F5
355 vein disease 9.4 VEGFA SERPINC1 PGF GPT F5 ALB
356 malaria 9.4 VEGFA VCAM1 SERPINC1 MMP9 GPT CFH
357 behcet syndrome 9.4 VEGFA VCAM1 SERPINC1 F5 APOH ALB
358 pulmonary artery disease 9.4 VEGFA SERPINC1 GPT F5 APOH ALB
359 retinal vascular occlusion 9.3 VEGFA SERPINC1 PGF F5 APOH
360 central retinal vein occlusion 9.3 VEGFA SERPINC1 PGF F5 APOH
361 retinal artery occlusion 9.3 VEGFA SERPINC1 PGF F5 APOH
362 diabetes mellitus 9.3 VEGFA VCAM1 SERPINC1 PAPPA MMP9 LEP
363 ischemic colitis 9.3 VEGFA SERPINC1 MMP9 HIF1A F5 APOH
364 diabetes mellitus, noninsulin-dependent 9.3 VEGFA VCAM1 PGF MMP9 LEP HIF1A
365 inflammatory bowel disease 9.2 VEGFA VCAM1 SERPINC1 MMP9 LEP HLA-G
366 heart disease 8.9 VEGFA VCAM1 SERPINC1 PGF MMP9 LEP
367 myocardial infarction 8.0 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

Symptoms:

12 (showing 1, show less)
  • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

45 (showing 12, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ALB APLN C3 CFH F5 FGR
2 homeostasis/metabolism MP:0005376 10.34 ALB APLN APOH C3 CFH F5
3 growth/size/body region MP:0005378 10.26 APLN C3 CFH F5 FN1 HIF1A
4 immune system MP:0005387 10.22 ALB C3 CFH FGR FN1 HIF1A
5 hematopoietic system MP:0005397 10.2 C3 CFH FGR FN1 HIF1A HLA-G
6 embryo MP:0005380 10.19 APLN C3 F5 FN1 HIF1A LEP
7 liver/biliary system MP:0005370 9.97 ALB C3 F5 FN1 HIF1A LEP
8 muscle MP:0005369 9.97 ALB APLN C3 CFH FN1 HIF1A
9 normal MP:0002873 9.81 ALB C3 CFH FGR FN1 HIF1A
10 neoplasm MP:0002006 9.8 ALB FN1 HIF1A LEP MMP9 PGF
11 renal/urinary system MP:0005367 9.56 ALB C3 CFH HIF1A LEP MMP9
12 vision/eye MP:0005391 9.28 APLN C3 CFH HIF1A LEP MMP9

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 158, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043 55185
2
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
3
Dalteparin Approved Phase 4 9005-49-6
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Pseudoephedrine Approved Phase 4 90-82-4 7028
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Captopril Approved Phase 4 62571-86-2 44093
10
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Anti-Infective Agents Phase 4
15 Anti-Bacterial Agents Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Sympatholytics Phase 4
18 Adrenergic Agonists Phase 4
19 Antibodies Phase 4
20 Immunoglobulins Phase 4
21 Antibodies, Antiphospholipid Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23 Central Nervous System Stimulants Phase 4
24 Vasoconstrictor Agents Phase 4
25 Vitamin B Complex Phase 4
26 Hematinics Phase 4
27 Folate Phase 4
28 Vitamin B9 Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30 Iron Supplement Phase 4
31 Lactoferrin Phase 4
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4
33 diuretics Phase 4
34 Sodium Channel Blockers Phase 4
35 Anesthetics, Local Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Analgesics Phase 4
38 Anesthetics Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Anticonvulsants Phase 4
41
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
42
Misoprostol Approved Phase 3 59122-46-2 5282381
43
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
44
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
45
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
46
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
47
Titanium dioxide Approved Phase 3 13463-67-7
48
Povidone Approved Phase 3 9003-39-8
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
50 Urapidil Investigational Phase 3 34661-75-1
51 Phosphodiesterase Inhibitors Phase 2, Phase 3
52 Citrate Phase 2, Phase 3
53 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
54 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
55 Gastrointestinal Agents Phase 3
56 Antacids Phase 3
57 Anti-Ulcer Agents Phase 3
58 Acetylsalicylic acid lysinate Phase 3
59 Cardiotonic Agents Phase 2, Phase 3
60 Protective Agents Phase 2, Phase 3
61 Serotonin Receptor Agonists Phase 3
62 Analgesics, Non-Narcotic Phase 3
63 Anti-Inflammatory Agents Phase 3
64 Antipyretics Phase 3
65 Cyclooxygenase Inhibitors Phase 3
66 Antirheumatic Agents Phase 3
67 Anti-Inflammatory Agents, Non-Steroidal Phase 3
68 Fibrinolytic Agents Phase 3
69 Platelet Aggregation Inhibitors Phase 3
70
Triacetin Phase 3 102-76-1 5541
71
Ethyl cellulose Phase 3 9004-57-3 24832091
72
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
73
Hydralazine Approved Phase 2 86-54-4 3637
74
Remifentanil Approved Phase 2 132875-61-7 60815
75
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 5311068 68602
76
Acetaminophen Approved Phase 2 103-90-2 1983
77
Ibuprofen Approved Phase 2 15687-27-1 3672
78
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
79
Ketorolac Approved Phase 2 66635-83-4, 74103-06-3 3826
80
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603
81
Pravastatin Approved Phase 2 81093-37-0 54687
82
Certolizumab pegol Approved Phase 2 428863-50-7
83 Rosuvastatin Calcium Phase 1, Phase 2 147098-20-2
84 Immunoglobulins, Intravenous Phase 2
85 Digitalis Phase 2
86 Immunoglobulin Fab Fragments Phase 2
87 Hypnotics and Sedatives Phase 2
88 Lipid Regulating Agents Phase 2
89 Hypolipidemic Agents Phase 2
90 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
91 Anticholesteremic Agents Phase 2
92 Antimetabolites Phase 2
93 Immunologic Factors Phase 2
94 calcium heparin Phase 2
95 Immunosuppressive Agents Phase 2
96 Angiogenesis Inducing Agents Phase 2
97
Methocarbamol Approved, Vet_approved Phase 1 532-03-6 4107
98
Vitamin C Approved, Nutraceutical Phase 1 50-81-7 5785 54670067
99 Antioxidants Phase 1
100 Trace Elements Phase 1
101 Vitamins Phase 1
102 Nutrients Phase 1
103 Micronutrients Phase 1
104
Methyldopa Approved 555-30-6 38853
105
Protein C Approved
106
Nimodipine Approved, Investigational 66085-59-4 4497
107
Diltiazem Approved, Investigational 42399-41-7 39186
108
Hydrocortisone Approved, Vet_approved 50-23-7 5754
109
Hydrocortisone acetate Approved, Vet_approved 50-03-3
110
Midazolam Approved, Illicit 59467-70-8 4192
111
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
112
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013